Miralles Gines Diego 4

What Happened
Miralles Gines, Diego (Director) was granted an award of options covering 19,000 shares of Contineum Therapeutics Class A common stock on 2026-06-26. The reported transaction is an award/grant (derivative) at $0.00 in the filing (i.e., an option grant rather than an open‑market purchase or sale). The Form 4 reports $0 as the acquisition price; the grant’s exercise (strike) price and immediate intrinsic value are not disclosed in the filing.

Key Details

• Transaction date: 2026-06-26; Filing date: 2026-06-26 (appears timely).
• Reported transaction type/code: A (award/grant); security type: derivative (stock option).
• Shares/options granted: 19,000; reported acquisition price: $0.00 (grant).
• Shares owned after transaction: Not specified in this Form 4.
• Footnote: Options were granted under the Issuer’s 2024 Equity Incentive Plan pursuant to the Non‑Employee Director Compensation Program. The options vest in full on the earlier of (i) June 26, 2027 (one‑year anniversary of grant) or (ii) the next regular annual meeting of stockholders, subject to continuous service.
• No evidence in this filing of an immediate exercise, sale, or tax‑withholding disposition.

Context
This is a routine non‑employee director compensation grant rather than a market purchase or insider sale. Option awards are common for board members and do not by themselves indicate buying or selling sentiment—realized value depends on future vesting, the option exercise price, and future share price. Monitor future filings for option exercises or any open‑market trades.